

The TIL-based therapies market is projected to be worth over USD 4.3 billion, by 2030, claims Roots Analysis

The TIL-based therapies market is projected to be worth over USD 4.3 billion, by 2030, claims Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, October 5, 2021 /EINPresswire.com/ -- Driven by the potential to confer sustained therapeutic effects and thereby, facilitate prolonged periods of remission, [TIL-based therapies](#) have received significant financial support, and promising leads are poised to soon achieve blockbuster status

[Roots Analysis](#) has announced the addition of “[TIL-based Therapies Market, 2021-2030](#)” report to its list of offerings.

To order this 255+ page report, which features 90+ figures and 100+ tables, please visit <https://www.rootsanalysis.com/reports/til-therapies-market.html>

Key Inclusions

▣ A detailed assessment of the current market landscape of TIL-based therapies with respect to type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (melanoma, ovarian cancer, pancreatic cancer, head and neck cancer, sarcoma, colon cancer, acute myeloid leukemia, stomach cancer, chronic lymphocytic leukemia, cervical cancer, breast cancer and others), source of T-cells (autologous and allogeneic), dose frequency (single

Example Highlights
A large number of prominent scientists from renowned academic and research institutes, are overseeing the clinical development efforts in this domain, and are some of the key opinion leaders in this field of research

TIL-based Therapies: Key Opinion Leaders
Regional Distribution^{1,2}

Most Prominent Key Opinion Leaders²

Phase of Development	Key Opinion Leader	Number of Trials
Phase III	Inga Marie Svane, Herlev Hospital, Biologic Design, Karolinska University Hospital	2 Trials
Phase II	Yves Borella, Johns Hopkins University; Anne R. Jassani, M.D., Anderson Cancer Center; M.D. Anderson Cancer Center	3 Trials
Phase I	George Coukos, Dana-Farber Cancer Institute; Roshdi M. Amaria, M.D., Anderson Cancer Center; Maki S. Konomi, Pillitteri Cancer Center; Steven A. Rosenberg, National Cancer Institute	24 Trials

Note 1: Highest phase of trials has been taken into consideration.
Note 2: Principal investigator listed in the article only as the most prominent KOLs as per our proprietary analysis.
Note 3: A detailed list of KOLs, having expertise related to TIL-based therapies, is presented in the report titled "TIL-based Therapies Market, 2021-2030".

TIL-based Therapies Market by Target

Example Highlights
Presently, close to 70 TIL-based immunotherapies are being evaluated, primarily for the treatment of a range of oncological indications; most of the product candidates are in phase I and phase II of clinical development

TIL Immunotherapies: Development Pipeline¹

S. No.	Therapy Name	Organization	Indication(s)	Therapeutic Area	Phase of Development	Route of Administration	Source of T-Cells	Type of Development
1	TILs		Melanoma	Solid Tumor	Phase III	Intravenous	Autologous	Non-Industry
8	Lifileucel (LN-144)	IONAVANCE	Melanoma	Solid Tumor	Phase II	Intravenous	Autologous	Industry
15	Donor Lymphocyte Infusion (DLI)	ANGEN	ALL	Hematological Cancer	Phase II	Intravenous	Allogeneic	Industry / Non-Industry
20	TGFβ/NIR1-transduced TILs	NOVATEL PARK	Solid Neoplasm					
26	COR1-TIL	中山大学	Cervical Carcinoma					
30	TILs	中山大学	Nasopharyngeal Carcinoma					
33	L-TIL	中山大学	Solid Tumors					
45	Donor Lymphocyte Infusion (DLI)	Novartis	AML, MS					
48	TILs	KAROLINSKA	Melanoma					
56	IOV-2001	IONAVANCE	CLL, SLL					
64	LTX-315 and TILs	Lyte Biopharma	Soft Tissue Sarcoma					
68	TILs	UHN	Melanoma, Pleural Mesothelioma					

Distribution by Therapeutic Area and Phase of Development

Phase of Development	Percentage
Phase III	3%
Phase II	38%
Phase I and II	45%
Preclinical	14%

65+ Pipeline Candidates

Abbreviations: ALL, Acute Lymphoblastic Leukemia; AML, Acute Myeloid Leukemia; MS, Multiple Sclerosis; CLL, Chronic Lymphocytic Leukemia; SLL, Small Lymphocytic Lymphoma.
Note 1: Complete list of TIL immunotherapies, along with information on various parameters, is available in the report titled "TIL-based Therapies Market, 2021-2030".

TIL-based Therapies Market by Target - RootsAnalysis

dose, multiple dose and split dose), target patient segment (children, adults and elderly patients) and type of therapy (monotherapy and combination therapy). Further, the chapter provides detail on the most active players (in terms of number of pipeline candidates) engaged in this domain.


□ An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2x2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of TIL-based therapies.

□ Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, current development status, key clinical trial results, dosage regimen and manufacturing information.

□ An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological disease indications.

□ An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.

□ An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies. The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public



TIL-based Therapies Market by Target Indications



offerings, grants, and debt financing.

□ A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers engaged in this market.

□ An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may adopt, in order to decide the price of a TIL-based therapy.

□ A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

□ Target Indication

□ Acute Lymphoblastic Leukemia

□ Melanoma

□ Others

□ Key Players

□ Key Geographical Regions

□ North America

□ Europe

□ Asia Pacific

To request a sample copy / brochure of this report, please visit
<https://www.rootsanalysis.com/reports/til-therapies-market.html>

Key Questions Answered

□ What are the prevalent R&D trends related to TIL-based therapies?

□ Who are the leading industry and non-industry players engaged in the development of TIL-based therapies?

□ What challenges are commonly faced by stakeholders engaged in this domain?

□ Who are the key investors in this domain?

□ Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?

□ Which types of partnership models are commonly adopted by industry stakeholders?

□ Which regions are key contract manufacturing hubs for TIL-based therapies?

□ Which factors are likely to influence the evolution of this upcoming market?

□ How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles:

1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. ICR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Gaurav Chaudhary

Roots Analysis

+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/553060628>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.